{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:52:23Z","timestamp":1792853543245,"version":"4.5.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen International GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40123-025-01104-3","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:45:49Z","timestamp":1740548749000},"page":"621-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Seenu M.","family":"Hariprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl V.","family":"Asche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Keady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad F.","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Sarocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"2","key":"1104_CR1","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/s2214-109x(20)30425-3","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators. Trends in prevalence of blindness and distance and near vision impairment over 30\u00a0years: an analysis for the global burden of disease study. Lancet Glob Health. 2021;9(2):e130\u201343. https:\/\/doi.org\/10.1016\/s2214-109x(20)30425-3.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"1104_CR2","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.3928\/23258160-20200401-01","volume":"51","author":"AA Moshfeghi","year":"2020","unstructured":"Moshfeghi AA, Lanitis T, Kropat G, et al. Social cost of blindness due to AMD and diabetic retinopathy in the United States in 2020. Ophthalmic Surg Lasers Imaging Retina. 2020;51(4):S6-S14. https:\/\/doi.org\/10.3928\/23258160-20200401-01.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"1104_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41433-021-01825-2","volume":"36","author":"JX Ong","year":"2022","unstructured":"Ong JX, Fawzi AA. Perspectives on diabetic retinopathy from advanced retinal vascular imaging. Eye (Lond). 2022;36(2):319\u201327. https:\/\/doi.org\/10.1038\/s41433-021-01825-2.","journal-title":"Eye (Lond)"},{"issue":"14","key":"1104_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.14.26","volume":"62","author":"PA Campochiaro","year":"2021","unstructured":"Campochiaro PA. Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture. Invest Ophthalmol Vis Sci. 2021;62(14):26. https:\/\/doi.org\/10.1167\/iovs.62.14.26.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1104_CR5","doi-asserted-by":"publisher","first-page":"04026","DOI":"10.7189\/jogh.12.04026","volume":"12","author":"Y Chen","year":"2022","unstructured":"Chen Y, Han X, Gordon I, et al. A systematic review of clinical practice guidelines for myopic macular degeneration. J Glob Health. 2022;12:04026. https:\/\/doi.org\/10.7189\/jogh.12.04026.","journal-title":"J Glob Health"},{"key":"1104_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050904","author":"A Ben-Arzi","year":"2022","unstructured":"Ben-Arzi A, Ehrlich R, Neumann R. Retinal diseases: the next frontier in pharmacodelivery. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14050904.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1104_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","volume":"11","author":"SM Hariprasad","year":"2022","unstructured":"Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R. An introduction to biosimilars for the treatment of retinal diseases: a narrative review. Ophthalmol Ther. 2022;11(3):959\u201382. https:\/\/doi.org\/10.1007\/s40123-022-00488-w.","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"1104_CR8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.18553\/jmcp.2021.27.9.1260","volume":"27","author":"A Almony","year":"2021","unstructured":"Almony A, Keyloun KR, Shah-Manek B, et al. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. J Manag Care Spec Pharm. 2021;27(9):1260\u201372. https:\/\/doi.org\/10.18553\/jmcp.2021.27.9.1260.","journal-title":"J Manag Care Spec Pharm"},{"key":"1104_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02407-0","author":"KV Vu","year":"2023","unstructured":"Vu KV, Mitchell P, Detaram HD, Burlutsky G, Liew G, Gopinath B. Risk factors for poorer quality of life in patients with neovascular age-related macular degeneration: a longitudinal clinic-based study. Eye (Lond). 2023. https:\/\/doi.org\/10.1038\/s41433-023-02407-0.","journal-title":"Eye (Lond)"},{"key":"1104_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1477-7525-4-97","volume":"4","author":"J Mitchell","year":"2006","unstructured":"Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97. https:\/\/doi.org\/10.1186\/1477-7525-4-97.","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"1104_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00592-020-01513-9","volume":"57","author":"F Fajnkuchen","year":"2020","unstructured":"Fajnkuchen F, Delyfer MN, Conrath J, et al. Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections. Acta Diabetol. 2020;57(9):1081\u201391. https:\/\/doi.org\/10.1007\/s00592-020-01513-9.","journal-title":"Acta Diabetol"},{"issue":"6","key":"1104_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/dme.14125","volume":"37","author":"OAE Cooper","year":"2020","unstructured":"Cooper OAE, Taylor DJ, Crabb DP, Sim DA, McBain H. Psychological, social and everyday visual impact of diabetic macular oedema and diabetic retinopathy: a systematic review. Diabet Med. 2020;37(6):924\u201333. https:\/\/doi.org\/10.1111\/dme.14125.","journal-title":"Diabet Med"},{"key":"1104_CR13","unstructured":"National Academies of Sciences E, Medicine, Health, et al. The National Academies Collection: reports funded by National Institutes of Health. In: Welp A, Woodbury RB, McCoy MA, Teutsch SM, editors. Making eye health a population health imperative: vision for tomorrow. Washington (DC)."},{"issue":"2","key":"1104_CR14","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/s2214-109x(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/doi.org\/10.1016\/s2214-109x(13)70145-1.","journal-title":"Lancet Glob Health"},{"key":"1104_CR15","unstructured":"Bright Focus Foundation. Age-related macular degeneration: facts & figures. 2023. https:\/\/www.brightfocus.org\/macular\/article\/age-related-macular-facts-figures. Accessed 18 Nov 2024."},{"issue":"1","key":"1104_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133. https:\/\/doi.org\/10.1186\/s12967-023-03937-7.","journal-title":"J Transl Med"},{"issue":"1","key":"1104_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100114","volume":"2","author":"CP Creuzot-Garcher","year":"2022","unstructured":"Creuzot-Garcher CP, Srour M, Baudin F, et al. Incidence and prevalence of neovascular age-related macular degeneration in France between 2008 and 2018: the LANDSCAPE study. Ophthalmol Sci. 2022;2(1):100114. https:\/\/doi.org\/10.1016\/j.xops.2022.100114.","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"1104_CR18","doi-asserted-by":"publisher","first-page":"2222545","DOI":"10.1080\/07853890.2023.2222545","volume":"55","author":"I Korva-Gurung","year":"2023","unstructured":"Korva-Gurung I, Kubin AM, Ohtonen P, Hautala N. Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland. Ann Med. 2023;55(1):2222545. https:\/\/doi.org\/10.1080\/07853890.2023.2222545.","journal-title":"Ann Med"},{"issue":"4","key":"1104_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/s0161-6420(00)00580-7","volume":"108","author":"W Smith","year":"2001","unstructured":"Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108(4):697\u2013704. https:\/\/doi.org\/10.1016\/s0161-6420(00)00580-7.","journal-title":"Ophthalmology"},{"issue":"1","key":"1104_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12886-017-0514-3","volume":"17","author":"M Elshout","year":"2017","unstructured":"Elshout M, Webers CA, van der Reis MI, de Jong-Hesse Y, Schouten JS. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. BMC Ophthalmol. 2017;17(1):120. https:\/\/doi.org\/10.1186\/s12886-017-0514-3.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"1104_CR21","doi-asserted-by":"publisher","first-page":"13152","DOI":"10.1038\/s41598-021-92567-4","volume":"11","author":"S Honda","year":"2021","unstructured":"Honda S, Yanagi Y, Koizumi H, et al. Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Sci Rep. 2021;11(1):13152. https:\/\/doi.org\/10.1038\/s41598-021-92567-4.","journal-title":"Sci Rep"},{"issue":"9","key":"1104_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.oftale.2020.11.008","volume":"96","author":"JI Fern\u00e1ndez-Vigo","year":"2021","unstructured":"Fern\u00e1ndez-Vigo JI, Burgos-Blasco B, Calvo-Gonz\u00e1lez C, et al. Assessment of vision-related quality of life and depression and anxiety rates in patients with neovascular age-related macular degeneration. Arch Soc Esp Oftalmol (Engl Ed). 2021;96(9):470\u20135. https:\/\/doi.org\/10.1016\/j.oftale.2020.11.008.","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"1","key":"1104_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-021-00290-z","volume":"7","author":"AB Roque","year":"2021","unstructured":"Roque AB, da Silva Borges GF, Abe RY, et al. The effects of age-related macular degeneration on quality of life in a Brazilian population. Int J Retina Vitreous. 2021;7(1):20. https:\/\/doi.org\/10.1186\/s40942-021-00290-z.","journal-title":"Int J Retina Vitreous"},{"issue":"12","key":"1104_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011504","volume":"6","author":"DJ Taylor","year":"2016","unstructured":"Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016;6(12): e011504. https:\/\/doi.org\/10.1136\/bmjopen-2016-011504.","journal-title":"BMJ Open"},{"key":"1104_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19020820","author":"D Caballe-Fontanet","year":"2022","unstructured":"Caballe-Fontanet D, Alvarez-Peregrina C, Busquet-Duran N, Pedemonte-Sarrias E, Andreu-V\u00e1zquez C, S\u00e1nchez-Tena M. Quality of life and anxiety in age macular degeneration patients: a cross-sectional study. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph19020820.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1104_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261897","volume":"17","author":"M Glatz","year":"2022","unstructured":"Glatz M, Riedl R, Glatz W, et al. Blindness and visual impairment in Central Europe. PLoS ONE. 2022;17(1):e0261897. https:\/\/doi.org\/10.1371\/journal.pone.0261897.","journal-title":"PLoS ONE"},{"issue":"3","key":"1104_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/08820538.2021.1962920","volume":"37","author":"H Hashemi","year":"2022","unstructured":"Hashemi H, Rezvan F, Pakzad R, et al. Global and regional prevalence of diabetic retinopathy; a comprehensive systematic review and meta-analysis. Semin Ophthalmol. 2022;37(3):291\u2013306. https:\/\/doi.org\/10.1080\/08820538.2021.1962920.","journal-title":"Semin Ophthalmol"},{"issue":"11","key":"1104_CR28","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.027.","journal-title":"Ophthalmology"},{"key":"1104_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061816","author":"W Wang","year":"2018","unstructured":"Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19061816.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1104_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00592-019-01384-9","volume":"56","author":"M Trento","year":"2019","unstructured":"Trento M, Charrier L, Cavallo F, et al. Vision-related quality of life and locus of control in type\u00a01 diabetes: a multicenter observational study. Acta Diabetol. 2019;56(11):1209\u201316. https:\/\/doi.org\/10.1007\/s00592-019-01384-9.","journal-title":"Acta Diabetol"},{"key":"1104_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213362","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11213362.","journal-title":"Cells"},{"issue":"3","key":"1104_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ophtha.2008.10.016","volume":"116","author":"R Klein","year":"2009","unstructured":"Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type\u00a01 diabetes. Ophthalmology. 2009;116(3):497\u2013503. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.016.","journal-title":"Ophthalmology"},{"issue":"4","key":"1104_CR33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351. https:\/\/doi.org\/10.1016\/j.survophthal.2022.01.009.","journal-title":"Surv Ophthalmol"},{"issue":"13","key":"1104_CR34","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1167\/iovs.16-19729","volume":"57","author":"C Aroney","year":"2016","unstructured":"Aroney C, Fraser-Bell S, Lamoureux EL, Gillies MC, Lim LL, Fenwick EK. Vision-related quality of life outcomes in the BEVORDEX study: a clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema. Invest Ophthalmol Vis Sci. 2016;57(13):5541\u20136. https:\/\/doi.org\/10.1167\/iovs.16-19729.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1104_CR35","unstructured":"IDF Diabetes Atlas. 2021. https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/. Accessed 18 Nov 2024."},{"key":"1104_CR36","unstructured":"The coming milestone in global aging. 2016. https:\/\/ifstudies.org\/blog\/the-coming-milestone-in-global-aging. Accessed 18 Nov 2024."},{"issue":"1","key":"1104_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/bjo.2007.122416","volume":"92","author":"SM Hariprasad","year":"2008","unstructured":"Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92(1):89\u201392. https:\/\/doi.org\/10.1136\/bjo.2007.122416.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1104_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/eye.2009.56","volume":"24","author":"A Gabrielian","year":"2010","unstructured":"Gabrielian A, Hariprasad SM, Jager RD, Green JL, Mieler WF. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life. Eye (Lond). 2010;24(1):29\u201335. https:\/\/doi.org\/10.1038\/eye.2009.56.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1104_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaophthalmol.2023.6435","volume":"142","author":"MG Zayed","year":"2024","unstructured":"Zayed MG, Karsan W, Peto T, Saravanan P, Virgili G, Preiss D. Diabetic retinopathy and quality of life: a systematic review and meta-analysis. JAMA Ophthalmol. 2024;142(3):199\u2013207. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.6435.","journal-title":"JAMA Ophthalmol"},{"key":"1104_CR40","unstructured":"Blair K, Czyz CN. Central retinal vein occlusion. StatPearls. Treasure Island (FL): StatPearls; 2023."},{"issue":"1","key":"1104_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3928\/23258160-20201223-06","volume":"52","author":"TR Rosenblatt","year":"2021","unstructured":"Rosenblatt TR, Vail D, Saroj N, Boucher N, Moshfeghi DM, Moshfeghi AA. Increasing incidence and prevalence of common retinal diseases in retina practices across the United States. Ophthalmic Surg Lasers Imaging Retina. 2021;52(1):29\u201336. https:\/\/doi.org\/10.3928\/23258160-20201223-06.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"1104_CR42","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427. https:\/\/doi.org\/10.7189\/jogh.09.010427.","journal-title":"J Glob Health"},{"key":"1104_CR43","volume-title":"Management of retinal vein occlusion: current concepts","author":"KG Kapoor","year":"2014","unstructured":"Kapoor KG, Bakri SJ. Retinal vein occlusion background. In: Hariprasad SM, editor. Management of retinal vein occlusion: current concepts. Chicago, Illinois: Slack; 2014."},{"key":"1104_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/nu14091801","author":"S Artale","year":"2022","unstructured":"Artale S, Grillo N, Lepori S, et al. A nutritional approach for the management of chemotherapy-induced diarrhea in patients with colorectal cancer. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14091801.","journal-title":"Nutrients"},{"issue":"8","key":"1104_CR45","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25(8):981\u20138. https:\/\/doi.org\/10.1038\/eye.2011.92.","journal-title":"Eye"},{"issue":"4","key":"1104_CR46","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/cxo.12875","volume":"102","author":"M Prem Senthil","year":"2019","unstructured":"Prem Senthil M, Khadka J, Gilhotra JS, et al. Understanding quality of life impact in people with retinal vein occlusion: a qualitative inquiry. Clin Exp Optom. 2019;102(4):406\u201311. https:\/\/doi.org\/10.1111\/cxo.12875.","journal-title":"Clin Exp Optom"},{"issue":"4","key":"1104_CR47","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ceo.14050","volume":"50","author":"H Kandel","year":"2022","unstructured":"Kandel H, Nguyen V, Piermarocchi S, et al. Quality of life impact of eye diseases: a save sight registries study. Clin Exp Ophthalmol. 2022;50(4):386\u201397. https:\/\/doi.org\/10.1111\/ceo.14050.","journal-title":"Clin Exp Ophthalmol"},{"key":"1104_CR48","volume-title":"Management of retinal vein occlusion: current concepts","author":"NM Holekamp","year":"2014","unstructured":"Holekamp NM, Ittiara ST. Anti-vascular endothelial growth factor therapies for retinal vein occlusion. In: Hariprasad SM, editor. Management of retinal vein occlusion: current concepts. Chicago Illinois: Slack; 2014."},{"issue":"3","key":"1104_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","volume":"99","author":"TY Wong","year":"2015","unstructured":"Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99(3):289\u201396. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305131.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1104_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271342","volume":"17","author":"M Jain","year":"2022","unstructured":"Jain M, Narayanan R, Jana P, et al. Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neo-vascularization. PLoS ONE. 2022;17(7):e0271342. https:\/\/doi.org\/10.1371\/journal.pone.0271342.","journal-title":"PLoS ONE"},{"key":"1104_CR51","unstructured":"Perez D. Myopic choroidal neovascularization. 2020. https:\/\/www.aao.org\/eyenet\/article\/myopic-choroidal-neovascularization. Accessed 18 Nov 2024."},{"issue":"11","key":"1104_CR52","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1097\/iae.0000000000001858","volume":"38","author":"NW Tan","year":"2018","unstructured":"Tan NW, Ohno-Matsui K, Koh HJ, et al. Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in east-Asian patients from the RADIANCE study. Retina. 2018;38(11):2228\u201338. https:\/\/doi.org\/10.1097\/iae.0000000000001858.","journal-title":"Retina"},{"issue":"1","key":"1104_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280311","volume":"18","author":"K Hirata","year":"2023","unstructured":"Hirata K, Matsumoto K, Hatakeyama Y, Onishi R, Seto K, Hasegawa T. Social burden of three major diseases in Japan: a time trend and future projections using the comprehensive cost of illness method. PLoS ONE. 2023;18(1):e0280311. https:\/\/doi.org\/10.1371\/journal.pone.0280311.","journal-title":"PLoS ONE"},{"key":"1104_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100852","volume":"35","author":"AP Marques","year":"2021","unstructured":"Marques AP, Ramke J, Cairns J, et al. Global economic productivity losses from vision impairment and blindness. EClinicalMedicine. 2021;35:100852. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100852.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"1104_CR55","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamaophthalmol.2016.1778","volume":"134","author":"PM Cumberland","year":"2016","unstructured":"Cumberland PM, Rahi JS. Visual function, social position, and health and life chances: the UK Biobank study. JAMA Ophthalmol. 2016;134(9):959\u201366. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.1778.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"1104_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2021.09.010","volume":"129","author":"DB Rein","year":"2022","unstructured":"Rein DB, Wittenborn JS, Zhang P, et al. The economic burden of vision loss and blindness in the United States. Ophthalmology. 2022;129(4):369\u201378. https:\/\/doi.org\/10.1016\/j.ophtha.2021.09.010.","journal-title":"Ophthalmology"},{"key":"1104_CR57","unstructured":"Canadian Council of the Blind. The cost of vision loss and blindness in Canada. 2021. https:\/\/www.fightingblindness.ca\/wp-content\/uploads\/2021\/12\/Deloitte-Cost-of-vision-loss-and-blindness-in-Canada-report-May-2021.pdf. Accessed 18 Nov 2024."},{"issue":"4","key":"1104_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/09286586.2017.1281426","volume":"24","author":"U Chakravarthy","year":"2017","unstructured":"Chakravarthy U, Biundo E, Saka RO, Fasser C, Bourne R, Little JA. The economic impact of blindness in Europe. Ophthalmic Epidemiol. 2017;24(4):239\u201347. https:\/\/doi.org\/10.1080\/09286586.2017.1281426.","journal-title":"Ophthalmic Epidemiol"},{"issue":"11","key":"1104_CR59","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/cer-2018-0058","volume":"7","author":"DH Jaffe","year":"2018","unstructured":"Jaffe DH, Chan W, Bezlyak V, Skelly A. The economic and humanistic burden of patients in receipt of current available therapies for nAMD. J Comp Eff Res. 2018;7(11):1125\u201332. https:\/\/doi.org\/10.2217\/cer-2018-0058.","journal-title":"J Comp Eff Res"},{"issue":"9","key":"1104_CR60","doi-asserted-by":"publisher","first-page":"A803","DOI":"10.1016\/j.jval.2017.08.2391","volume":"20","author":"A Skelly","year":"2017","unstructured":"Skelly A, Ferreira A, Bezlyak V, Jaffe D. PSS13 - the economic and humanistic burden of patients on treatment for neovascular age-related macular degeneration. Value Health. 2017;20(9):A803. https:\/\/doi.org\/10.1016\/j.jval.2017.08.2391.","journal-title":"Value Health"},{"issue":"16 Suppl","key":"1104_CR61","first-page":"S311","volume":"25","author":"JM Coney","year":"2019","unstructured":"Coney JM. Addressing unmet needs in diabetic retinopathy. Am J Manag Care. 2019;25(16 Suppl):S311\u20136.","journal-title":"Am J Manag Care"},{"issue":"5","key":"1104_CR62","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1185\/030079908x297303","volume":"24","author":"LJ Lee","year":"2008","unstructured":"Lee LJ, Yu AP, Cahill KE, et al. Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin. 2008;24(5):1549\u201359. https:\/\/doi.org\/10.1185\/030079908x297303.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1104_CR63","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol. 2018;66(12):1736\u201350. https:\/\/doi.org\/10.4103\/ijo.IJO_1240_18.","journal-title":"Indian J Ophthalmol"},{"issue":"11","key":"1104_CR64","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1097\/iae.0000000000000217","volume":"34","author":"IJ Su\u00f1er","year":"2014","unstructured":"Su\u00f1er IJ, Margolis J, Ruiz K, Tran I, Lee P. Direct medical costs and resource use for treating central and branch retinal vein occlusion in commercially insured working-age and Medicare populations. Retina. 2014;34(11):2250\u20138. https:\/\/doi.org\/10.1097\/iae.0000000000000217.","journal-title":"Retina"},{"key":"1104_CR65","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/opth.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391. https:\/\/doi.org\/10.2147\/opth.S185052.","journal-title":"Clin Ophthalmol"},{"key":"1104_CR66","doi-asserted-by":"publisher","first-page":"4683427","DOI":"10.1155\/2016\/4683427","volume":"2016","author":"Z Khan","year":"2016","unstructured":"Khan Z, Braich PS, Rahim K, et al. Burden and depression among caregivers of visually impaired patients in a Canadian population. Adv Med. 2016;2016:4683427. https:\/\/doi.org\/10.1155\/2016\/4683427.","journal-title":"Adv Med"},{"issue":"6","key":"1104_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198631","volume":"13","author":"AP Marques","year":"2018","unstructured":"Marques AP, Macedo AF, Hernandez-Moreno L, et al. The use of informal care by people with vision impairment. PLoS ONE. 2018;13(6):e0198631. https:\/\/doi.org\/10.1371\/journal.pone.0198631.","journal-title":"PLoS ONE"},{"key":"1104_CR68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/ppa.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604. https:\/\/doi.org\/10.2147\/ppa.S347713.","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 2","key":"1104_CR69","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00347-021-01411-7","volume":"118","author":"LO Hattenbach","year":"2021","unstructured":"Hattenbach LO, Heinz P, Feltgen N, et al. Impact of the SARS-CoV-2 pandemic on ophthalmic care in Germany. Ophthalmologe. 2021;118(Suppl 2):166\u201375. https:\/\/doi.org\/10.1007\/s00347-021-01411-7.","journal-title":"Ophthalmologe"},{"issue":"6","key":"1104_CR70","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.survophthal.2022.08.002","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Dharia RS, Yan P. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67(6):1593\u2013602. https:\/\/doi.org\/10.1016\/j.survophthal.2022.08.002.","journal-title":"Surv Ophthalmol"},{"key":"1104_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100131","volume":"12","author":"M Syriga","year":"2021","unstructured":"Syriga M, Karampela I, Dalamaga M, Karampelas M. The effect of COVID-19 pandemic on the attendance and clinical outcomes of patients with ophthalmic disease: a mini-review. Metabol Open. 2021;12: 100131. https:\/\/doi.org\/10.1016\/j.metop.2021.100131.","journal-title":"Metabol Open"},{"issue":"12","key":"1104_CR72","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1038\/s41433-022-02149-5","volume":"36","author":"R Gale","year":"2022","unstructured":"Gale R, Cox O, Keenan C, Chakravarthy U. Health technology assessment of new retinal treatments; the need to capture healthcare capacity issues. Eye (Lond). 2022;36(12):2236\u20138. https:\/\/doi.org\/10.1038\/s41433-022-02149-5.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1104_CR73","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/iae.0000000000002888","volume":"41","author":"TE Greenlee","year":"2021","unstructured":"Greenlee TE, Wang VY, Kang H, et al. Consequences of lapses in treatment with vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration in routine clinical practice. Retina. 2021;41(3):581\u20137. https:\/\/doi.org\/10.1097\/iae.0000000000002888.","journal-title":"Retina"},{"issue":"10","key":"1104_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018289","volume":"7","author":"W Hollingworth","year":"2017","unstructured":"Hollingworth W, Jones T, Reeves BC, Peto T. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open. 2017;7(10):e018289. https:\/\/doi.org\/10.1136\/bmjopen-2017-018289.","journal-title":"BMJ Open"},{"issue":"3","key":"1104_CR75","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/pts.0000000000000188","volume":"14","author":"N Shehab","year":"2018","unstructured":"Shehab N, Brown MN, Kallen AJ, Perz JF. US compounding pharmacy-related outbreaks, 2001\u20132013: public health and patient safety lessons learned. J Patient Saf. 2018;14(3):164\u201373. https:\/\/doi.org\/10.1097\/pts.0000000000000188.","journal-title":"J Patient Saf"},{"issue":"3","key":"1104_CR76","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00417-019-04569-8","volume":"258","author":"T Bro","year":"2020","unstructured":"Bro T, Derebecka M, J\u00f8rstad \u00d8K, Grzybowski A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):503\u201311. https:\/\/doi.org\/10.1007\/s00417-019-04569-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1104_CR77","unstructured":"EMA. Lytenava, bevacizumab. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lytenava. Accessed 18 Nov 2024."},{"issue":"5","key":"1104_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006535","volume":"5","author":"T Butt","year":"2015","unstructured":"Butt T, Lee A, Lee C, Tufail A. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes. BMJ Open. 2015;5(5):e006535. https:\/\/doi.org\/10.1136\/bmjopen-2014-006535.","journal-title":"BMJ Open"},{"issue":"7","key":"1104_CR79","doi-asserted-by":"publisher","first-page":"608","DOI":"10.18553\/jmcp.2018.24.7.608","volume":"24","author":"L Hernandez","year":"2018","unstructured":"Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Intravitreal aflibercept versus ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2018;24(7):608\u201316. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.608.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1104_CR80","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2337\/dc22-2527","volume":"46","author":"K Mulligan","year":"2023","unstructured":"Mulligan K, Kim J, Tysinger B, et al. The broader economic value of treatment for diabetic macular edema. Diabetes Care. 2023;46(6):1196\u2013203. https:\/\/doi.org\/10.2337\/dc22-2527.","journal-title":"Diabetes Care"},{"issue":"3","key":"1104_CR81","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12325-019-0894-2","volume":"36","author":"G McCarthy","year":"2019","unstructured":"McCarthy G, Fenu E, Bennett N, Almond C. Intravitreal ranibizumab for the treatment of visual impairment due to choroidal neovascularization associated with rare diseases: cost-effectiveness in the UK. Adv Ther. 2019;36(3):632\u201344. https:\/\/doi.org\/10.1007\/s12325-019-0894-2.","journal-title":"Adv Ther"},{"key":"1104_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081869","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9081869.","journal-title":"Cells"},{"issue":"5","key":"1104_CR83","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3928\/23258160-20210429-01","volume":"52","author":"R Narayanan","year":"2021","unstructured":"Narayanan R, Hariprasad SM, Sheth J. Biosimilars for the treatment of retinal diseases. Ophthalmic Surg Lasers Imaging Retina. 2021;52(5):242\u20136. https:\/\/doi.org\/10.3928\/23258160-20210429-01.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1104_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103894","volume":"181","author":"P Gasc\u00f3n","year":"2023","unstructured":"Gasc\u00f3n P, Goldsmith D, Aapro M, Dellanna F, Esmael A, Zabransky M. Epoetin alfa biosimilar (HX575): a review of 15\u00a0years\u2019 post-approval clinical experience. Crit Rev Oncol Hematol. 2023;181:103894. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103894.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1104_CR85","unstructured":"IQVIA. The impact of biosimilar competition in Europe. 2020. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2021.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR86","unstructured":"Biosimilars Council. Biosimilar medicines generated $7 billion in savings in 2021. 2022. https:\/\/biosimilarscouncil.org\/news\/biosimilar-medicines-generated-7-billion-in-savings-in-2021. Accessed 18 Nov 2024."},{"issue":"2","key":"1104_CR87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","volume":"34","author":"B Dutta","year":"2020","unstructured":"Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34(2):159\u201370. https:\/\/doi.org\/10.1007\/s40259-019-00395-w.","journal-title":"BioDrugs"},{"issue":"4","key":"1104_CR88","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.survophthal.2024.03.009","volume":"69","author":"NM Bressler","year":"2024","unstructured":"Bressler NM, Kaiser PK, Do DV, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: a review. Surv Ophthalmol. 2024;69(4):521\u201338. https:\/\/doi.org\/10.1016\/j.survophthal.2024.03.009.","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"1104_CR89","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14712598.2023.2239706","volume":"23","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia. Expert Opin Biol Ther. 2023;23(8):689\u201392. https:\/\/doi.org\/10.1080\/14712598.2023.2239706.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"1104_CR90","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/iae.0000000000002670","volume":"40","author":"FG Holz","year":"2020","unstructured":"Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina. 2020;40(9):1673\u201385. https:\/\/doi.org\/10.1097\/iae.0000000000002670.","journal-title":"Retina"},{"issue":"3","key":"1104_CR91","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/aos.14262","volume":"98","author":"IS Kristiansen","year":"2020","unstructured":"Kristiansen IS, Haugli Br\u00e5ten R, J\u00f8rstad \u00d8K, Moe MC, Saether EM. Intravitreal therapy for retinal diseases in Norway\u00a02011\u20132015. Acta Ophthalmol. 2020;98(3):279\u201385. https:\/\/doi.org\/10.1111\/aos.14262.","journal-title":"Acta Ophthalmol"},{"key":"1104_CR92","doi-asserted-by":"publisher","unstructured":"Edmunds M, Sloan FA, Steinwald AB. Geographic adjustment in Medicare payment. Phase\u00a0II: implications for access, quality, and efficiency. National Academies Press (US); 2012. https:\/\/doi.org\/10.17226\/13420.","DOI":"10.17226\/13420"},{"issue":"10","key":"1104_CR93","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258(10):2077\u201390. https:\/\/doi.org\/10.1007\/s00417-020-04798-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1104_CR94","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060.","journal-title":"Ophthalmology"},{"issue":"11","key":"1104_CR95","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","volume":"136","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol. 2018;136(11):1251\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3578.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"1104_CR96","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/iae.0000000000003626","volume":"42","author":"PK Kaiser","year":"2022","unstructured":"Kaiser PK, Schmitz-Valckenberg MS, Holz FG. Anti-vascular endothelial growth factor biosimilars in ophthalmology. Retina. 2022;42(12):2243\u201350. https:\/\/doi.org\/10.1097\/iae.0000000000003626.","journal-title":"Retina"},{"issue":"4","key":"1104_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055478","volume":"12","author":"JV Rocha","year":"2022","unstructured":"Rocha JV, Marques AP, Macedo AF, et al. Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013\u20132018): a retrospective analysis of administrative data. BMJ Open. 2022;12(4):e055478. https:\/\/doi.org\/10.1136\/bmjopen-2021-055478.","journal-title":"BMJ Open"},{"issue":"7","key":"1104_CR98","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41433-021-01646-3","volume":"36","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. 2022;36(7):1373\u20138. https:\/\/doi.org\/10.1038\/s41433-021-01646-3.","journal-title":"Eye"},{"key":"1104_CR99","unstructured":"The White House. Executive order on promoting competition in the American economy. 2021. https:\/\/www.whitehouse.gov\/briefing-room\/presidential-actions\/2021\/07\/09\/executive-order-on-promoting-competition-in-the-american-economy\/. Accessed 18 Nov 2024."},{"key":"1104_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010048","author":"I Gherghescu","year":"2020","unstructured":"Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics13010048.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1104_CR101","doi-asserted-by":"publisher","first-page":"Isac001","DOI":"10.1093\/jlb\/lsac001","volume":"9","author":"VL Van de Wiele","year":"2022","unstructured":"Van de Wiele VL, Hammer M, Parikh R, Feldman WB, Sarpatwari A, Kesselheim AS. Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases. J Law Biosci. 2022;9(1):Isac001. https:\/\/doi.org\/10.1093\/jlb\/lsac001.","journal-title":"J Law Biosci"},{"key":"1104_CR102","doi-asserted-by":"crossref","unstructured":"Keady S, Rickard I, Xin Q, et al. Utilisation of the cost-saving impact of biosimilar switching in ophthalmological diseases in the NHS: a case study for a ranibizumab biosimilar. Poster EE313. Presented at The Professional Society for Health Economics and Outcomes Research (ISPOR), Boston, MA, USA. 7\u201310 May 2023.","DOI":"10.1016\/j.jval.2023.03.614"},{"key":"1104_CR103","doi-asserted-by":"crossref","unstructured":"Keady S, Goyert-Stephens N, Xin Q, et al. A comparison of the cost-saving impact of biosimilar switching policies across Canadian provinces: a case study for a ranibizumab biosimilar. Poster EE426. Presented at The Professional Society for Health Economics and Outcomes Research (ISPOR), Boston, MA, USA. 7\u201310 May 2023.","DOI":"10.1016\/j.jval.2023.03.727"},{"issue":"6","key":"1104_CR104","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ecco-jcc\/jjw216","volume":"11","author":"V Razanskaite","year":"2017","unstructured":"Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw216.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1104_CR105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-020-00456-5","volume":"35","author":"E Moorkens","year":"2021","unstructured":"Moorkens E, Vulto AG, Kent J, et al. A look at the history of biosimilar adoption: characteristics of early and late adopters of infliximab and etanercept biosimilars in subregions of England, Scotland and Wales - a mixed methods study. BioDrugs. 2021;35(1):75\u201387. https:\/\/doi.org\/10.1007\/s40259-020-00456-5.","journal-title":"BioDrugs"},{"issue":"5","key":"1104_CR106","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11096-021-01243-0","volume":"43","author":"B Duggan","year":"2021","unstructured":"Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-\u03b1 inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021;43(5):1251\u20136. https:\/\/doi.org\/10.1007\/s11096-021-01243-0.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"1104_CR107","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jval.2023.04.007","volume":"26","author":"E Moorkens","year":"2023","unstructured":"Moorkens E, Lacosta TB, Dawoud D, et al. A systematic literature review of gaps and challenges in value assessment of biosimilars: an ISPOR special interest group report. Value Health. 2023;26(8):1137\u201344. https:\/\/doi.org\/10.1016\/j.jval.2023.04.007.","journal-title":"Value Health"},{"key":"1104_CR108","unstructured":"Biogen. Samsung bioepis biosimilar market report 3rd edition, Q4 2023. https:\/\/www.samsungbioepis.com\/upload\/attach\/SB+Biosimilar+Market+Report+Q4+2023.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR109","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2147\/opth.S407219","volume":"17","author":"D Chakraborty","year":"2023","unstructured":"Chakraborty D, Mondal S, Boral S, et al. Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (the BALANCE trial): real-world evidence. Clin Ophthalmol. 2023;17:1067\u201376. https:\/\/doi.org\/10.2147\/opth.S407219.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"1104_CR110","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40123-021-00345-2","volume":"10","author":"D Chakraborty","year":"2021","unstructured":"Chakraborty D, Stewart MW, Sheth JU, et al. Real-world safety outcomes of intravitreal ranibizumab biosimilar (razumab) therapy for chorioretinal diseases. Ophthalmol Ther. 2021;10(2):337\u201348. https:\/\/doi.org\/10.1007\/s40123-021-00345-2.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"1104_CR111","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40123-022-00507-w","volume":"11","author":"M Soman","year":"2022","unstructured":"Soman M, Nair I, Sheth JU, Nair U. Innovator versus biosimilar ranibizumab in polypoidal choroidal vasculopathy: real-world evidence. Ophthalmol Ther. 2022;11(3):1175\u201386. https:\/\/doi.org\/10.1007\/s40123-022-00507-w.","journal-title":"Ophthalmol Ther"},{"key":"1104_CR112","unstructured":"Finger RP, Nguyen TH, Hatfield M, Addison J. Ranibizumab biosimilar in nAMD \u2013 early insights from the IRIS\u00ae Registry database. e-Poster\u00a0CA24-2208-3191. Presented at EURETINA. Barcelona, Spain. 19\u201322 Sept 2024."},{"key":"1104_CR113","unstructured":"Hariprasad SM, Trotter J, Arkin-Leydig K, Nguyen TH, Utzinger M, Addison J. Outcomes in nAMD following intravitreal anti-VEGF (reference and biosimilar): pilot study of the IRIS\u24c7 Registry. Poster PO541. Presented at the American Academy of Ophthalmology (AAO). San Francisco, USA. 3\u20136 Nov 2023."},{"key":"1104_CR114","unstructured":"FDA. FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions. 2024. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye. Accessed 18 Nov\u00a02024."},{"key":"1104_CR115","unstructured":"EMA. Lucentis ranibizumab. 2007. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lucentis#ema-inpage-item-product-info. Accessed 18 Nov 2024."},{"key":"1104_CR116","unstructured":"EMA. Eylea (aflibercept). 2012. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eylea. Accessed 18 Nov 2024."},{"key":"1104_CR117","unstructured":"EMA. Beovu (brolucizumab). 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beovu. Accessed 18 Nov 2024."},{"key":"1104_CR118","unstructured":"EMA. Syfovre (pegcetacoplan). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/syfovre. Accessed 18 Nov 2024."},{"key":"1104_CR119","unstructured":"EMA. Summary of product characteristics: VABYSMO. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR120","unstructured":"FDA. Highlights of prescribing information: SUSVIMO\u2122 (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761197s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR121","unstructured":"FDA. Highlights of prescribing information: VABYSMO\u2122 (faricimab-svoa) injection, for intravitreal use. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR122","unstructured":"FDA. Izervay highlights of prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217225s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR123","unstructured":"FDA.gov. Lucentis (ranibizumab) injection. 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125156s0000_LucentisTOC.cfm#:~:text=Approval%20Date%3A%2006%2F30%2F2006. Accessed 18 Nov 2024."},{"key":"1104_CR124","unstructured":"FDA.gov. Eylea (aflibercept) injection. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR125","unstructured":"FDA.gov. FDA-approved biosimilar products. 2023. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed 18 Nov 2024."},{"key":"1104_CR126","unstructured":"FDA.gov. SYFOVRE prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217171s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR127","unstructured":"GBI. Generics and biosimilars initiative. 2023. https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-europe. Accessed 18 Nov 2024."},{"key":"1104_CR128","unstructured":"Genentech. Genentech to reintroduce Susvimo for people with wet age-related macular degeneration (AMD). Genentech; 2024."},{"key":"1104_CR129","unstructured":"Lim JI. An update on the anti-VEGF biosimilar pipeline. 2023. https:\/\/www.reviewofophthalmology.com\/article\/an-update-on-the-antivegf-biosimilar-pipeline. Accessed 18 Nov 2024."},{"key":"1104_CR130","unstructured":"Hutton D. FDA approves aflibercept injection 8 mg for treatment of wet AMD, DME, DR. 2023. Ophthalmology Times: News, 2023 August 19. Available from: https:\/\/www.ophthalmologytimes.com\/view\/hed-fda-approves-aflibercept-injection-8mg-for-treatment-of-wet-amd-dme-dr. Accessed Nov 2024."},{"key":"1104_CR131","unstructured":"Hayes H. European Commission grants EU marketing authorisation for aflibercept (Eylea) 8 mg. Ophthalmology Times: News, 2024 January 8. Available from: https:\/\/europe.ophthalmologytimes.com\/view\/european-commission-grants-eu-marketing-authorisation-for-aflibercept-eylea-8-mg. Accessed Nov 2024."},{"key":"1104_CR132","unstructured":"EMA. Yesafili. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yesafili. Accessed 18 Nov 2024."},{"key":"1104_CR133","unstructured":"EMA. Summary of product characteristics: ranibizumab midas. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ranibizumab-midas-epar-product-information_en.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR134","unstructured":"FDA. Highlights of prescribing information: PAVBLU. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761298s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR135","unstructured":"FDA. Highlights of prescribing information: AHZANTIVE. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761378s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR136","unstructured":"FDA. Highlights of prescribing information: OPUVIZ. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761350s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR137","unstructured":"FDA. Highlights of prescribing information: YESAFILI. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761274s000lbl.pdf. Accessed 18 Nov 2024."},{"key":"1104_CR138","unstructured":"Sandoz Group. Sandoz receives FDA approval for Enzeevu\u2122 (aflibercept-abzv), further strengthening US biosimilar position. 2024. https:\/\/www.globenewswire.com\/news-release\/2024\/08\/12\/2928076\/0\/en\/Sandoz-receives-FDA-approval-for-Enzeevu-aflibercept-abzv-further-strengthening-US-biosimilar-position.html. Accessed Nov 2025."},{"key":"1104_CR139","unstructured":"Retina International. AMD impact: cost of illness study. 2022. https:\/\/retina-international.org\/amd-impact-cost-of-illness-study\/. Accessed 18 Nov 2024."},{"key":"1104_CR140","unstructured":"CDS. Health and economic costs of chronic diseases. 2023. https:\/\/www.cdc.gov\/chronic-disease\/data-research\/facts-stats\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/chronicdisease\/about\/costs\/index.htm. Accessed 18 Nov 2024."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01104-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01104-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01104-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:09:08Z","timestamp":1742342948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01104-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01104-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seenu M. Hariprasad is a consultant or on the speakers' bureau for Bayer, Allergan\/AbbVie, Coherus, Astellas\/Iveric Bio, Alimera Sciences, Biogen, Harrow and Regeneron. Frank G. Holz reports research grants and consulting fees from Acucela, Allergan, Apellis, Bayer, Bioeq\/Formycon, Roche\/Genentech, Geuder, Heidelberg Engineering, Astellas\/ivericBio, Pixium Vision, Novartis, Zeiss; consulting fees from Alexion, Alzheon, Annexon, Astellas, Boehringer-Ingelheim, Grayburg Vision, Janssen, LinBioscience, Stealth BioTherapeutics, Aerie, Oxurion. Carl V. Asche has no conflicts of interest. Amine Issa, Oriol Mora and Mourad F. Rezk are employees of Biogen International GmbH and may hold stock in Biogen. Simon Keady and Phil Sarocco are former employees of Biogen. Their new affiliations are: Phil Sarocco, Halozyme, Inc., employee and shareholder; Simon Keady, Galderma (UK) Ltd, employee. Steven Simoens is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). He was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer, Organon and Amgen; he has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma and Pfizer; and he has had speaking engagements for Abbott, Amgen, Biogen, Celltrion and Sandoz.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}